Cargando…
Regulatory network analysis defines unique drug mechanisms of action and facilitates patient-drug matching in alopecia areata clinical trials
Not all therapeutics are created equal in regards to individual patients. The problem of identifying which compound will work best with which patient is a significant burden across all disease contexts. In the context of autoimmune diseases such as alopecia areata, several formulations of JAK/STAT i...
Autores principales: | Chen, James C., Dai, Zhenpeng, Christiano, Angela M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403543/ https://www.ncbi.nlm.nih.gov/pubmed/34504667 http://dx.doi.org/10.1016/j.csbj.2021.08.026 |
Ejemplares similares
-
Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
por: Dai, Zhenpeng, et al.
Publicado: (2021) -
Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
por: Dai, Zhenpeng, et al.
Publicado: (2022) -
Molecular signatures define alopecia areata subtypes and transcriptional biomarkers
por: Jabbari, Ali, et al.
Publicado: (2016) -
The Changing Landscape of Alopecia Areata: The Translational Landscape
por: Wang, Etienne C. E., et al.
Publicado: (2017) -
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
por: Jabbari, Ali, et al.
Publicado: (2015)